Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

  • In development
  • GID-TA11477
  • Expected publication date: TBC

The appraisal has been delayed following a request from the company.

NIHRIO BN: 13408-Semaglutide-for-Non-Alcoholic-Steatohepatitis-V1.0-OCT2023-NON-CONF.pdf (nihr.ac.uk)